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ABSTRACT 
Effect of Oral Lipids on Blood Glucose 
Tyler R. Knisley 
 
Diabetes mellitus is a disease in which insulin hormone is ineffective or no longer 
produced. Multiple pathophysiologies can cause either insulin dependent diabetes 
mellitus (IDDM) or insulin independent diabetes mellitus (IIDM), which can lead to 
chronic hyperglycemia and an array of short and long term health risks. Prior research 
has shown that IDDM patients have dyslipidemia, and experiments infusing lipids 
directly into the blood result in heightened insulin resistance. The hypothesis that 
dyslipidemia increases insulin resistance was tested by performing oral glucose tolerance 
tests across three treatment conditions. Participants were nondiabetic college-aged 
students. Data from a control group was gathered and analyzed against a lipid and 
carbohydrate treatment. The lipid group showed the greatest increase in glucose level at 
any single time period, but the carbohydrate group remained steadily elevated throughout 
the three hour testing window. Analysis of the data showed the only significant difference 
existed between the carbohydrate and dextrose treatments, meaning the original 
hypothesis could not be supported. For future testing, it is recommended that each test 
group contain all the same subjects and a longer fasting period is given after the 
carbohydrate treatment is consumed. The research and experiments were condensed into 
a lab protocol so students enrolled in BMED 460 may further extend their knowledge of 
diabetes and help lead the future of treatment and device innovation. 
 
 
 
 
 
 
 
 
 
 
Keywords: Insulin Independent Diabetes Mellitus, Dyslipidemia, Hyperglycemia,  
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Chapter 1. Introduction 
Diabetes mellitus affects over 25 million Americans and its prevalence is 
increasing as people are living longer [1]. Over one quarter of these cases are found in 
senior patients older than 65, and across all age groups, it is estimated that over 7 million 
affected individuals have yet to be diagnosed [1]. There are two common types of 
diabetes: insulin dependent diabetes mellitus (IDDM), also known as type 1, and insulin 
independent diabetes mellitus (IIDM), also known as type 2. Insulin is a hormone that 
activates a signaling cascade which allows for the transport of glucose molecules from 
the blood stream and interstitium to myofibers and adipocytes. These tissues may then 
utilize the glucose for cell growth and survival. Both forms of diabetes result in improper 
glucose transport and hyperglycemia (elevated blood sugar levels). Over time, this 
chronic hyperglycemia causes major health complications, including kidney failure, 
lower limb amputation, blindness, stroke, and heart disease [1]. Overall, diabetes is the 
seventh-highest cause of death in the United States. 
 
Background 
There are three forms of diabetes, IDDM, IIDM, and gestational, each with 
differing etiologies and pathophysiologies. IDDM, also known as “Juvenile Diabetes,” 
occurs when patients are no longer able to produce insulin. Scientists believe this is 
caused by a combination of genetics and environmental factors, specifically a viral 
infection [2]. These factors trigger an autoimmune disease that slowly but permanently 
attack the insulin-producing β-cells of the pancreas [3]. Once they are destroyed, the 
pancreas produces minimal to zero new insulin for the rest of the patient’s life. This 
2 
 
absence of insulin prevents glucose from being properly transported to muscle and 
adipose tissue, and can cause hyperglycemia. IDDM may develop at any age, but is most 
often diagnosed in children or young adults [4].  
IIDM is the most common form of diabetes, and coupled with the growing obesity 
problem in America, is evolving into an “epidemic.” In 2010, the Center for Disease 
Control and Prevention estimated that over 79 million Americans had prediabetes [1]. 
While a diagnosis of insulin resistance (prediabetes) does not guarantee these patients 
will develop IIDM, it indicates their blood glucose is consistently higher than normal and 
if left untreated, the condition is likely to progress [5].  
The fat, liver, and muscle cells of IIDM patients do not properly respond to 
insulin. Due to this, sugar remains in the blood stream and is not properly utilized by 
these specific cells [6]. IIDM is often called “Insulin Resistant Diabetes” because of this. 
This buildup of sugars, or hyperglycemia, slowly increases the risk of additional 
complications occurring. Risks of developing IIDM depend on family history, excess 
body weight, and dietary habits involving high lipid intake. 
The least common and most temporary type is gestational diabetes, which can 
occur around week 20 of pregnancy [7]. This is thought to be caused by the increased 
levels of estrogen, cortisol, and human placental lactogen, which can inhibit insulin from 
initiating glucose transport [8]. Gestational diabetes is often addressed without the need 
for medication or insulin shots. The most important concern is monitoring fetal health by 
measuring the fetal body size and heart rate to ensure it is developing correctly [7]. 
Women who become pregnant at older ages and who are overweight before conception 
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are at higher risks of developing this condition. However, unless the mother was diabetic 
before her pregnancy, this disorder normally disappears after parturition.  
 
Insulin and Glucose Signaling Pathways 
The etiology of diabetes can be explained by the interactions between insulin and 
glucose molecules, which are shown in Figure 1. Insulin is a hormone produced by the 
endocrine portion of the pancreas, and its release is stimulated by postprandial 
hyperglycemia. The endocrine portion is composed of millions of cell clusters called 
Islets of Langerhans. Over 75% of these cell clusters are β-cells, which are responsible 
for producing insulin molecules and then releasing them from the pancreatic islets [9]. 
Insulin’s main metabolic function is activating the signaling cascade that causes glucose 
transport to skeletal myofibers and adipocytes, as well as reducing gluconeogenesis in the 
liver [10].  
 
 
Figure 1:  Diagrams of a simple glucose (C6H12O6) and complex insulin molecule [11, 12]. 
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intracellular-signaling molecules and help specific proteins bind to appropriate receptors 
[14]. The IRS recruit phosphoinositide-3-kinase to the cell membrane, where it 
phosphorylates phosphatidylinositol 4,5-bisphosphate (PIP2) into PIP3. This step 
activates a protein kinase B-dependent pathway, which increases the metabolic effects of 
insulin and also causes GLUT-4 glucose transporter proteins to be inserted into the cell 
membranes of myofibers and adipocytes. 
This pathway can be antagonized by hyperlipidemia. Lipids are broken down into 
diacylglycerol, which physiologically activate protein kinase C (PKC) to phosphorylate 
IRS on serine residues. This activation of serine, instead of tyrosine, phosphorylation 
occurs upstream in the insulin signaling pathway and stops the signal from advancing, 
contributing to insulin resistance. 
Understanding these pathways is crucial to analyzing additional health risks and 
creating both therapies and better diabetes management devices.  
 
Health Risks 
 While IDDM and IIDM lead to many of the same health problems, IIDM is 
much more prevalent, accounting for up to 90% of all diabetics [10]. Because poor health 
and dieting have a strong association with these patients, it is necessary to understand 
how these factors, especially dyslipidemia, impact the body’s signaling of insulin and the 
relations of IIDM to insulin resistance. 
Acutely, hyperglycemia is the buildup of glucose in the blood, which means cells 
that rely on this glucose for energy sources are not getting it properly transported to them. 
As a result, extra lipids are broken down into 2-carbon molecules, which are able to 
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undergo cellular respiration and produce ATP [15]. This shift towards lipid metabolism 
produces an increase in acetyl coenzyme A (acetyl-CoA), which is derived from fatty 
acids. The additional acetyl-CoA that the mitochondria cannot metabolize is converted 
into toxins called ketones. If this extreme hyperglycemic condition is not reversed, 
diabetic ketoacidosis may occur which can put the patient into a diabetic coma [16].   
Similar to ketoacidosis, diabetic hyperosmolar syndrome occurs when insulin 
levels are slightly deficient, but lipolysis and ketogenesis are avoided [17]. While insulin 
is present, it is not functioning properly, which inhibits the body from using either 
glucose or fat for energy metabolism [16]. A hyperglycemic environment will still exist, 
and even after the kidneys filter the blood, some excess glucose will be present in the 
preurine. This decreases water reabsorption and will cause patients to urinate more 
frequently [18]. If untreated, this syndrome may also lead to a diabetic coma and critical 
dehydration levels.   
These acute conditions can often be avoided with frequent blood-glucose 
monitoring. Slight levels of transient hyperglycemia will occur naturally, but testing will 
allow for earlier detection and quicker treatment. However, lengthened periods of 
hyperglycemia over many years can cause chronic conditions such as cardiovascular 
disease, retinopathy, nephropathy, neuropathy, and non-healing ulcers. Additionally, 
IIDM is often associated with metabolic syndrome, a condition caused by diets with 
elevated cholesterol and triglyceride levels [19]. Metabolic syndrome is diagnosed when 
any three of the following three conditions are present: excess adiposity in the patient’s 
midsection, dyslipidemia, decreased high-density lipoprotein (HDL) levels, hypertension, 
and fasting hyperglycemia [19].  
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While metabolic syndrome has varying pathophysiologies, the primary effects of 
chronic hyperglycemia are due to endothelial dysfunction. Diabetic patients are shown to 
have increased production of reactive oxygen species and decreased bioavailability of 
endothelial nitric oxide [20]. As vascular superoxide (O2-) reacts with the lessened levels 
of nitric oxide, it produces peroxynitrite (ONOO-) which inhibits receptors and enzymes 
that remove free radicals [20]. Excess free radicals contribute to the vasoconstriction that 
occurs in adverse cardiovascular diseases including atherosclerosis. The American Heart 
Association attributes cardiovascular disease as the cause of death in at least 65% of 
diabetic patients, and finds these same people to be two to four times more likely to 
develop heart disease or have a stroke than non-diabetic adults [21].  
Chronic hyperglycemia can also affect vision. Diabetic retinopathy, or a disorder 
concerning the retina, is the most common condition [22]. Nonproliferative retinopathy 
occurs when inflammation occludes the capillaries in the back of the eye. Vision loss is 
rare at this stage, and often no treatment is necessary as long as the patient keeps better 
control of their blood glucose fluctuations [23]. This condition can progress to 
proliferative retinopathy when a large number of capillaries are occluded, stimulating 
angiogenesis, or new capillary growth in the retina. Due to their immaturity, blood may 
leak from newly formed capillaries, causing vitreous hemorrhage or scar tissue to form 
[22]. Retinopathy at this stage may result in partial or total vision loss that may be 
permanent. 
Another common effect of diabetes is nephropathy. The nephron is the functional 
unit of the kidney that is responsible for filtering blood. Chronic hyperglycemia causes 
the kidneys to filter more blood, which damages them and makes the nephrons less 
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efficient over time. Waste from the kidneys begins to leak and albumin is passed into the 
urine [24]. Diabetic nephropathy is the leading cause of kidney failure in the United 
States [25]. Because early-stage symptoms are often not shown, routine blood tests 
should be conducted so specialists may diagnosis if a patient is at risk. 
A final health risk is dyslipidemia, or increased levels of lipids and lipoproteins in  
the blood. This can be caused by chronic hyperglycemia and insulin resistance over time.  
Insulin resistance causes high triglyceride levels and increases production of very low-
density lipoproteins (VLDL) and low-density lipoproteins (LDL), the pro-atherogenic 
forms of cholesterol. Average levels of the anti-atherogenic cholesterol, HDL, are 
decreased as they are rapidly depleted by transporting the excess LDL to the liver [26]. 
Excess LDL can pass through the endothelial layer and become oxidized and 
endocytosed by macrophages, which transforms them into foam cells, causing 
atherosclerosis and intimal thickening via hyperplasia, which can restrict blood 
circulation [9]. 
            These health risks, coupled with the number of existing and future patients, 
necessitate more research be done to better understand and treat diabetes. The goal of this 
research is to develop a laboratory protocol for BMED 460 students at Cal Poly, San Luis 
Obispo. This protocol will lead students through a physiology experiment in which they 
will determine the consistency of an oral glucose tolerance test (OGTT), and test the 
hypothesis that lipid consumption increases insulin resistance. Upon completion of this 
experiment, students will be able to describe how insulin signaling becomes impaired 
when diacylglycerol levels rise and ultimately how IRS phosphorylation becomes 
dysregulated.  
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Chapter 2. Methods 
 Participants were five college-aged, non-diabetic students with no known health 
conditions. Due to the length of each trial run, not every participant was involved in 
every treatment. 
 
Oral Glucose Tolerance Test 
Oral glucose tolerance tests were performed similar to the clinical procedure 
outlined by the National Health and Nutrition Examination Survey [27]. Participants 
fasted for approximately nine hours before drinking a solution containing seventy-five 
grams of glucose (Azer Scientific). In a hospital, the patient’s blood glucose level would 
be tested via venipuncture two hours after the glucose treatment. For this experiment, 
however, readings were taken in thirty minute intervals for three hours using a OneTouch 
Ultra glucose meter where the subject would prick their finger with a lancet device and 
use this blood for the measurement. 
  
Lipid and Carbohydrate Treatments 
After fasting between eight and ten hours, participants of the lipid treatment 
consumed 16 ounces of 70% lean / 30% fat cooked ground beef, which included 136 g of 
fat and 360 mg of cholesterol, or 208% and 120% of the respective daily recommended 
values. Subjects fasted for three additional hours to allow for gastric clearance, at which 
time the OGTT was performed as before [28]. 
Subjects in the carbohydrate treatment fasted for eight to ten hours, and then 
consumed pasta made with white flour. This meal totaled 168 g of carbohydrates, or 56% 
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of the daily recommended value. The white flour acts as a source of simple carbohydrates 
that will be transported to myofibers and hepatocytes to be stored as glycogen. After 
consuming the pasta, subjects were not allowed to eat for one hour to give the stomach 
time to void, after which the OGTT was performed as per to the two previous treatments 
[29]. 
Statistical Analysis 
 The data is presented as mean ± standard. A one-way ANOVA test was 
performed test the hypothesis that one of the treatments impaired glucose transport, 
followed by a Tukey post hoc test. 
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Chapter 3.  Results 
 
To create a representative curve, an OGTT with no additional treatments was 
performed. Following glucose consumption, participants tested their blood sugar every 
thirty minutes for three hours. Average values of the four trials are shown in Figure 3. 
 
Figure 3:  Average glucose levels plotted against time. 
 
As Figure 3 shows, a quick increase in glucose levels occurs during the first hour, after 
which, levels steadily decline to the original baseline reading. 
 Once the OGTT’s consistency was established, the hypothesis that an increase of 
lipids would increase insulin resistance was tested. The carbohydrate treatment was 
included as a control for how insulin responds to an influx of carbohydrates with no 
additional variables affecting insulin resistance. The average values from the lipid and 
carbohydrate treatments are combined in Figure 4. 
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Figure 4:  Average glucose levels of the lipid (diamond) and carbohydrate (square) treatments 
plotted against time. 
 
The lipid values have the highest average glucose value at thirty minutes. They also seem 
to have two slight “plateaus,” and at the final monitored time point, return close to the 
initial baseline reading. The blood glucose levels following the carbohydrate treatment 
were considerably higher and oscillated around 115 mg·dl-1 for the duration of the trial. 
 Statistical analysis was then performed to determine if the null hypothesis needed 
to be rejected. A single factor ANOVA test calculated a p-value of 0.00675, showing that 
a significant difference existed between at least two of the treatment groups. The 
complete results of this test can be found in Table I located in Appendix A. A Tukey test 
provided further analysis, and showed a significant difference existed between the 
carbohydrate and dextrose treatments. No differences were found when comparing the 
lipid test to either of the other treatments.  
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Chapter 4.  Discussion 
 
Diabetes is being diagnosed with greater frequency in the United States. IIDM is 
affecting over 25 million Americans, and is extending into younger age groups. 
Hyperglycemia and dyslipidemia associated with this disease can cause fatal health 
effects if left untreated over time. Previous studies, such as the one performed by The 
Howard Hughes Medical Institute and Yale University School of Medicine, have studied 
how free fatty acids effect the transportation of glucose to muscle tissue [26]. The 
objective of this senior project was similar in that it analyzed the effects of dyslipidemia 
on insulin resistance by performing OGTTs. 
In order to analyze the effect of excess lipids, an OGTT had to be performed with 
no additional treatments to show its consistency, Figure 3. The blood sugar levels peaked 
at thirty minutes, and then steadily declined back to the baseline value at around two 
hours. In a clinical setting, readings greater than 200 mg·dl-1 after two hours deem the 
patient diabetic, although the test will be ran identically on a following day to ensure 
correct results. If this reading falls between 140-199 mg·dl-1, the patient is considered to 
be prediabetic and at serious risk of developing diabetes even if no other symptoms are 
present [27]. 
With this consistency determined, the hypothesis that excess lipid levels increase 
insulin resistance could be tested by comparing the results of an OGTT after a lipid-rich 
and carbohydrate-rich meal was consumed. 
The OGTT following ingestion of carbohydrates, Figure 4, resulted in fairly 
horizontally linear values, neither showing a definitive peak nor declining to a normal 
fasting glucose level. This may have been due to the fact that once insulin secretion is 
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The OGTT following the lipid treatment showed the highest average value of 135 
mg·dl-1 at the thirty minute mark. It also had two “plateaus,” and while it eventually 
returned to the baseline reading, it took longer than the dextrose treatment to do so. A 
possible explanation for this is that gastric emptying of a high-fat meal is decreased and 
levels of glucagon-like peptide-1 (GLP-1) are increased [30]. One effect of slower gastric 
emptying is that it takes longer for glucose to enter the stomach and circulate through the 
body, which means that less insulin is released. For this senior project, this fact was 
accounted for by the three hour wait time between consuming the lipid-rich meal and 
performing the OGTT. The increase in GLP-1 may have factored into the decreasing 
glucose levels of the lipid treatment as it neared the three hour testing mark. GLP-1, 
which is secreted from L cells in the intestine, stimulates insulin secretion and inhibits 
glucagon secretion; both of which lower blood glucose levels [30]. The increase of GLP-
1 was unaccounted for and may explain why no significant difference in blood sugar 
levels existed between the lipid and other two treatments.  
Another explanation for statistical differences not existing between the lipid and 
carbohydrate treatments may have been that gastric emptying was not complete before 
the OGTT of the carbohydrate treatment. Although subjects waited an hour after eating, 
future tests should incorporate an additional thirty minutes of fasting. This adjustment 
will hopefully keep the carbohydrate blood sugar levels fairly constant, but within a 
lower range that may produce results significantly different from the lipids. If this 
occurred, it would support the hypothesis that lipid-rich meals increase insulin resistance 
through the phosphorylation of IRS onto serine amino acids instead of tyrosine amino 
acids.  
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Relevance to BMED 460 
 This study may be used to supplement the BMED 460 curriculum. While the 
insulin pathways are already included in this course, these results provide additional 
information on factors that affect insulin resistance and their compounding health effects 
if diabetes is left untreated. If a lab is implemented, it will give students hands-on insight 
to what diabetic patients must live through on a daily basis. With this disease being so 
prevalent, this experience may stimulate students to develop treatments and innovate 
existing medical devices. 
 
Conclusion 
 This study was not able to support the hypothesis that lipid-rich meals increase 
insulin resistance. However, there was evidence to suggest that some resistance was 
occurring, and if this experiment was performed again, a few changes to the experimental 
design can be suggested. Mainly, extend the post-carbohydrate consumption fasting 
period to ninety minutes, and include a larger sample size of nondiabetic subjects. 
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Appendix A – Statistical Data 
 
Table I: Results for Single Factor ANOVA Test 
 
Source  DF    SS    MS     F      P 
Factor   2  3695  1848  6.69  0.007 
Error   18  4970   276 
Total   20  8665 
 
S = 16.62   R-Sq = 42.65%   R-Sq(adj) = 36.27% 
 
 
                                 Individual 95% CIs For Mean Based on 
                                 Pooled StDev 
Level          N    Mean  StDev  ----+---------+---------+---------+----- 
Dextrose       7   81.75  18.15  (--------*-------) 
Carbohydrates  7  113.91   6.92                       (--------*--------) 
Lipids         7  101.86  21.23               (--------*--------) 
                                 ----+---------+---------+---------+----- 
                                    75        90       105       120 
 
Pooled StDev = 16.62 
 
Table II: Results for Tukey Test 
 
Grouping Information Using Tukey Method 
 
               N    Mean  Grouping 
Carbohydrates  7  113.91  A 
Lipids         7  101.86  A B 
Dextrose       7   81.75    B 
 
Means that do not share a letter are significantly different. 
 
 
Dextrose subtracted from: 
               Lower  Center  Upper  ----+---------+---------+---------+----- 
Carbohydrates   9.49   32.16  54.83                    (--------*--------) 
Lipids         -2.56   20.11  42.78               (--------*--------) 
                                     ----+---------+---------+---------+----- 
                                       -25         0        25        50 
Carbohydrates subtracted from: 
           Lower  Center  Upper   ----+---------+---------+---------+----- 
Lipids    -34.72 -12.04  10.63    (--------*--------) 
                                    ----+---------+---------+---------+----- 
           -25         0        25        50    
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Appendix B – Student Protocol 
 
OGTT and Insulin Signaling Pathway 
In this experiment, you will explore type 2 diabetes and the insulin signaling pathway on a 
macroscopic level by performing an Oral Glucose Tolerance Test (OGTT).
 
Background 
Diabetes affects over 8% of the American population. Directly, it is the seventh leading cause of 
death in the country. Indirectly, it is a primary factor of kidney failure, lower limb amputation, 
and blindness, along with playing a role in hypertension and numerous cardiovascular 
complications. It has become an epidemic and affects people of all ages. Type 2 diabetes, in 
particular, is the most common and often avoidable form of this disease. Type 2 diabetics 
experience insulin resistance which results in sustained elevated blood sugar levels.   
This experiment will provide a review of the insulin signaling pathway to show how elevated 
glucose levels promote insulin secretion, along with the mechanism insulin uses to metabolize 
this excess glucose and help keep the body in homeostasis. Students will then get the chance to 
undergo an OGTT. This is the same process hospitals use to screen patients who are believed to 
be at risk of having or developing diabetes. 
The hormone insulin is a primary factor in regulating blood sugar levels for all humans. Insulin is 
produced by β-cells located in the endocrine portion of the pancreas, but what signals it to be 
released into the blood stream? Glucose triggers the first signaling pathway which is responsible 
for regulating insulin secretion (Figure 1). As the glucose travels through the blood, it uses a 
GLUT-2 transporter in the liver to enter a β-cell. Once here, it uses a glucokinase (“glucose 
sensor”) to phosphorylate G6P. More glucose means more available energy, which increases the 
ATP:ADP ratio and closes ATP-sensitive potassium channels. Making these channels unavailable 
causes the β-cell membrane to depolarize and upregulate calcium-ion channels. The main effect 
of this is the exocytosis of insulin secretory granules from the β-cell out into the bloodstream. 
 Figure 1:  Cellular pathway depicting the events from glucose entering the 
The goal of the OGTT is to expose the body to a large amount of gluc
time. The body then produce
will be quantitatively measured 
Naturally, there will be an in
after consumption. If a patient’s blood sugar is 
considered to have prediabetes and further testing will need to be performed.
Ultimately, this lab is trying to give engineering students first
routines diabetic patients have 
more improvements to monitoring devices and
lead to fewer medical complications and h
place. 
Required Equipment
• Lancet Device 
• Lancets 
• Glucose Monitor 
• Glucose Monitor Test Strips (at least 7 per person)
• Glucose Solution (1 per person)
• Sanitizing Alcohol Wipes
 
β
secretion. 
ose in a short period of 
s and secretes insulin to naturally metabolize this excess sugar. 
using a glucose monitoring device at specified time intervals. 
itial spike in glucose levels. The key reading will occur two
above 140 mgdl-1 at this point, they may be 
 
-hand exposure to some of the 
to commit to on a daily basis. With this experience, more and 
 regulatory drugs can be made. Ultimately this will 
opefully fewer instances of the disease in the first 
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-cell to insulin 
This 
 hours 
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Procedure 
Exercise: Oral Glucose Tolerance Test 
1. Change the lancet. To do this, unscrew the top of the lancet device. Using a new lancet, 
“cap” the old one already in the mechanism. The old one can be pulled straight out and 
the new one inserted. To disconnect the two, move the old one in a circular motion until 
it becomes loose and separates. Finally, screw the top of the lancet device back on.  
 Note: To prevent the possible spread of bloodborne pathogens, always 
swap the lancet out for a new one.   
 
2. Insert a test strip into the glucose meter. A number should appear, followed by a flashing 
symbol which indicates it is ready to read a blood sample (Figure 2). 
 
 
Figure 2:  This flashing symbol indicates that the meter is ready to receive a blood sample. 
 
3. Choose which finger will be pricked (They should be rotated for each test, and never use 
the thumb), and clean the skin with an alcohol wipe. Wait a few seconds for the skin 
surface to dry.   
 
4. Pull back the slider on the lancet device to “arm” it. Hold it against the tip of the finger, 
preferably on the side, and press in on the white button. The lancet will quickly project 
outward and produce a small drop of blood (Figure 3). Note: Additional blood may need 
to be squeezed out to adequately fill the test trip. If squeezing does not work, the depth 
at which the lancet projects may be adjusted using the knob at the top of the lancet 
device.   
 
 
Figure 3:  A drop of blood after using the lancet device on the side and tip of finger. 
 
5. Slowly feed the drop of blood into the test strip. Once they come in contact with one 
another, the test strip should act like a vacuum and “pull” the blood in. 
 
6. The glucose meter will count down 5 seconds and then display a result. This number is 
the blood sugar level measured in units of mgdl-1
 
(Figure 4). If the display shows 
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“Er#,” this generally means not enough blood was gathered and an accurate reading 
could not be made. Remove the test strip and repeat the above steps to record an 
accurate measurement.   
 
 
Figure 4: If all the previous steps are performed correctly, an accurate reading will look 
like this. 
 
7. This first value is the Baseline reading before any treatment has been applied and occurs 
at “Time = 0 minutes.” After recording this first value, students will drink the solution of 
75 mg of glucose. Blood sugar will then be tested every 30 minutes following steps 1-6 
with the data being recorded in a table similar to this for each student: 
Time 
(min) 
Glucose Level 
(mgdl-1) 
0   
30   
60   
90   
120   
150   
180   
 
8. Because this experiment involves blood, make sure all surfaces remain clean and all used 
materials are disposed of properly. 
Analysis 
 
1. Traditionally, a doctor will require the patient to fast for 8-10 hours before the OGTT is done. 
Why is this important? If a meal is consumed two hours before the test, what may be some 
effects it has on the results? 
2. For the group’s data, plot the average values at each testing time point in Excel (Scatter plot 
with smooth lines and markers). At what time is the glucose level the highest? The lowest? 
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3. Here is the data for four patients that consumed a carbohydrate-rich meal one hour before 
an OGTT:  
Time Trial #1 Trial #2 Trial #3 Trial #4 
0 110 151 83 111 
30 125 136 98 144 
60 121 130 74 137 
90 105 99 101 117 
120 115 117 110 123 
150 107 104 107 105 
180 104 115 111 129 
 
Do statistical differences exist at any time points between data from this test and what your 
group recorded? What statistical test(s) did you use and why?  
 
Figure Preparation 
To complete the data analysis, create two figures to display your data. The first figure will be the 
Excel plot of your group’s averaged data. The second figure will be an Excel plot of both your 
average collected data and the average carbohydrate treatment data given in Problem 3. If 
statistical significances exist, be sure to make note of them on the graph.  
All bar charts must include a white background, standard error bars, no gridlines, axes labels, 
legend (if necessary) within chart area, figure caption, no figure title, and statistical significance 
indicated. 
Laboratory Report 
To complete the laboratory, you will write a laboratory report (less than 2 pages) that includes 
introduction, methods, results, and discussion sections.  
In the introduction section, you explain why a particular injury or disease-state is important to 
study and how recruitment, summation, max force, and/or fatigue rate can be used to assess the 
injury or disease state.  
The methods should briefly describe how the data were collected, such that an experienced 
researcher could repeat your experiments from the methods section alone.  
The results should include your figures and objective conclusions of the data (i.e. what).  
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The discussion section should include subjective interpretation(s) of the data (i.e. why), 
explanations for any technical/methodological difficulties, and suggestions for future applications 
of the utilized technique.  
The report must also include a title, the team name, and all team members’ names in the upper 
right-hand corner. 
 
 
